Emergent BioSolutions Sustainability Profile
Emergent BioSolutions Inc., a leading biopharmaceutical company headquartered in the United States, specialises in developing and manufacturing vaccines and therapeutics for public health threats. Founded in 1998, the company has achieved significant milestones, including the acquisition of key assets that bolster its position in the biodefence and infectious disease sectors. With a strong operational presence across North America and Europe, Emergent BioSolutions focuses on core products such as vaccines for anthrax and smallpox, as well as treatments for opioid overdose. What sets the company apart is its commitment to addressing urgent health needs through innovative solutions and strategic partnerships. Recognised for its expertise in biodefence, Emergent BioSolutions continues to play a pivotal role in enhancing global health security.
DitchCarbon Score
How does Emergent BioSolutions's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Emergent BioSolutions's score of 43 is higher than 62% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Emergent BioSolutions's reported carbon emissions
In 2024, Emergent BioSolutions reported total carbon emissions of approximately 12,800,000 kg CO2e for Scope 1 and about 14,812,000 kg CO2e for Scope 2, resulting in combined emissions of around 27,357,000 kg CO2e. This marks a reduction from 2023, where the company recorded Scope 1 emissions of about 16,856,000 kg CO2e and Scope 2 emissions of approximately 18,436,000 kg CO2e, totalling around 35,292,000 kg CO2e. In 2022, the emissions were even higher, with Scope 1 at about 19,334,000 kg CO2e and Scope 2 at around 21,099,000 kg CO2e, leading to a total of approximately 40,434,000 kg CO2e. Emergent BioSolutions has not disclosed any Scope 3 emissions data, nor have they set specific reduction targets through initiatives such as the Science Based Targets initiative (SBTi). The company has not made any formal climate pledges or commitments to reduce emissions, indicating a potential area for future focus. Overall, while the company has shown a downward trend in Scope 1 and 2 emissions over the past few years, the absence of comprehensive reduction targets and Scope 3 data suggests that further commitments may be necessary to enhance their climate strategy.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 19,334,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 21,099,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - |
How Carbon Intensive is Emergent BioSolutions's Industry?
How Carbon Intensive is Emergent BioSolutions's Location?
Emergent BioSolutions's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Emergent BioSolutions has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
